How to Apply for the Q-Line Biotech IPO: Step-by-Step Investment Guide

Summary:
 

Q-Line Biotech Ltd. operates in the in-vitro diagnostics (IVD) segment and is engaged in the manufacturing and supply of diagnostic reagents, consumables, and healthcare diagnostic equipment. The Q-Line Biotech IPO is scheduled to open on May 21, 2026, and close on May 25, 2026. The IPO consists of 62,53,200 equity shares with a price band of ₹326 to ₹343 per share. The company plans to utilise the proceeds towards working capital requirements, repayment of certain borrowings, and general corporate purposes. The shares are proposed to be listed on the SME platform of NSE.

Q-Line Biotech Ltd. operates in the in-vitro diagnostics (IVD) segment and is engaged in the development, manufacturing, marketing, import, and distribution of diagnostic reagents, consumables, and healthcare diagnostic equipment. The company supplies products to hospitals, diagnostic laboratories, medical colleges, and healthcare service providers through direct channels and distributor networks. Its business operations include segments such as clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and point-of-care diagnostic solutions. Its operations are supported by manufacturing facilities involved in the production of diagnostic kits and reagents across multiple categories. The company’s product portfolio and supply network have contributed to its presence within the healthcare diagnostics market. Q-Line Biotech Ltd. continues to operate in a sector influenced by increasing healthcare awareness, diagnostic testing requirements, and the adoption of preventive healthcare practices across India.

Investors can apply for the Q-Line Biotech Ltd IPO through the ASBA (Application Supported by Blocked Amount) process available via net banking platforms offered by authorised banks. Applicants are required to log in to their banking portal, select the IPO section, choose the Q-Line Biotech Ltd IPO, enter the bid quantity and price within the specified price band, and submit the application using their PAN details and demat account information. The application amount remains blocked in the bank account until the allotment process is completed. Applications can also be submitted through UPI-supported IPO platforms provided by registered stockbrokers and trading applications. Investors need to select the IPO, enter bidding details, provide their UPI ID, and approve the mandate request through the UPI application before the specified deadline. Investors are required to ensure that their demat account, PAN details, and bank account information are updated and linked correctly before applying for the IPO.

For more details, visit the Q-Line Biotech IPO page.

Q-Line Biotech IPO Details and Objectives

Details

Information

IPO Date

May 21, 2026 to May 25, 2026

Issue Size

62,53,200 shares (agg. up to ₹214.48 Cr)

Price Band

₹326 to ₹343 per share

Lot Size

400 shares

Listing At

SME, NSE 

Market Maker

Hem Finlease Pvt. Ltd. 

Purpose of the IPO

  • To meet working capital requirements

  • Repayment of certain borrowing availed by the company, in part or full

  • General corporate purposes

Timeline of Q-Line Biotech IPO

Event

Date

IPO Open Date

Thu, May 21, 2026 

IPO Close Date

Mon, May 25, 2026

Tentative Allotment

Tue, May 26, 2026 

Initiation of Refunds

Wed, May 27, 2026

Credit of Shares to Demat

Wed, May 27, 2026 

Tentative Listing Date

Fri, May 29, 2026

Cut-off time for UPI mandate confirmation

5 PM on Mon, May 25, 2026  

Pricing & Lot Size of Q-Line Biotech IPO

Price Band for the IPO

  • ₹326 to ₹343 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Individual investors (Retail) (Min)

2

800

₹2,74,400

Individual investors (Retail) (Max)

2

800

₹2,74,400

S-HNI (Min)

3

1,200

₹4,11,600

S-HNI (Max)

7

2,800

₹9,60,400

B-HNI (Min)

8

3,200

₹10,97,600

Q-Line Biotech IPO Application Process

The Q-Line Biotech IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

Step 1: Login to Your Trading Platform

Access your trading account using the trading platform.

Step 2: Navigate to the IPO Section

Go to the IPO section to view active IPO listings.

Step 3: Select the Open IPO and Click Apply

Locate Q-Line Biotech IPO in the list of available IPOs and click the ‘Apply’ button.

Step 4: Enter the Quantity of Shares You Wish to Apply For

Specify the number of shares (lot size: 400 shares) within the price band of ₹326 to ₹343 per share.

Step 5: Provide Your UPI ID

Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

Step 6: Confirm the Application

Review your application details and confirm the UPI mandate before 5 PM on the last application day.

Step 7: Complete the Process and Wait for IPO Allotment Status

Submit the application and monitor the allotment status to check if shares have been allocated to you.

Shares Offered in Q-Line Biotech IPO

The allocation of shares in the Q-Line Biotech IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.

 

Investor Category

Shares Offered

% of Net Issue

% of Total Issue

QIB Shares Offered

29,69,200

49.99%

47.48%

– Anchor Investor Shares Offered

17,81,200

28.48%

– QIB (Ex. Anchor) Shares Offered

11,88,000

19.00%

NII (HNI) Shares Offered

8,91,600

15.01%

14.26%

Retail Shares Offered

20,79,200

35.00%

33.25%

Firm Reservations

Market Maker Shares Offered

3,13,200

5.01%

Total Shares Offered

62,53,200

100.00%

100.00%

This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹251.58 crore in FY23 to ₹455.49 crore as of March 2025.

  • Total Income: Recorded at ₹322.58 crore in March 2025, as compared to ₹184.81 crore in FY23.

  • Profit After Tax (PAT): Reported at ₹28.13 crore in March 2025, and ₹32.10 crore in FY23.

  • Net Worth: Recorded at ₹189.95 crore in March 2025 compared to ₹127.37 crore in FY23.

  • Reserves & Surplus: Stood at ₹188.37 crore in March 2025, as compared to ₹125.79 crore in FY23.

  • Total Borrowings: Stood at ₹164.95 crore in March 2025, as compared to ₹73.65 crore in FY23.

  • EBITDA: Stood at ₹71.32 crore in March 2025 in comparison to ₹32.98 crore in FY23.

Recent Performance and Growth Prospects

  • The company reported growth in its asset base, reflecting expansion in operational scale and business activities over the reviewed period.

  • Revenue generation showed an upward trend, supported by increased business operations within the diagnostics and healthcare segment.

  • Operating performance improved during the period, indicating changes in business efficiency and operational activities.

  • The company also reported growth in net worth and reserves, which reflects changes in its overall financial position.

  • Borrowings increased during the period, highlighting a higher reliance on external funding for operational or expansion-related requirements.

  • Profitability remained subject to fluctuations despite growth across several financial and operational areas.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company reported an increase in total borrowings over the reviewed period, which may lead to higher financial obligations and repayment-related commitments.

  • Profit after tax reflected fluctuations despite growth in revenue, assets, and operational performance, indicating variations in overall profitability during the period under review.

Opportunities and Growth Potential

  • The company operates in the in-vitro diagnostics and healthcare diagnostics segment, which continues to witness demand supported by diagnostic testing requirements and preventive healthcare awareness in India.

  • Growth in total income, operational performance, asset base, net worth, and reserves reflects expansion in business activities, manufacturing operations, and distribution capabilities across its product segments.

Key Performance Indicator (KPI)

KPI

Dec 31, 2025

Mar 31, 2025

ROE

16.88%

17.66%

ROCE

13.32%

23.74%

Debt/Equity

1.06

0.87

RoNW

16.88%

23.74%

PAT Margin

16.65%

8.97%

EBITDA Margin

27.64%

22.73%

Q-Line Biotech IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Purva Sharegistry (India) Pvt. Ltd.

Hem Securities Ltd., Share India Capital Services Pvt. Ltd.

Company Address of Q-Line Biotech Ltd

298-281,

Transport Nagar,

Kanpur Road, Adjacent Transport Nagar Metro Station,

Lucknow, Uttar Pradesh, 226012

Phone: +91 522-2435570

Email: compliance@qlinebiotech.com

Website: https://qlinebiotech.com/

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Q-Line Biotech IPO allotment status.

Frequently Asked Questions

Published Date : 20 May 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

QR code to download Bajaj Broking App

9 lakh+ Users

icon-with-text

4.9 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300 Cr+ MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|